Jazz Pharmaceuticals Canada enters into LoI with pCPA for Rylaze

Jazz Pharmaceuticals Canada Inc. today announced that the company has entered into a Letter of Intent with the pan-Canadian Pharmaceutical Alliance regarding Rylaze in Canada. This allows for individual jurisdictions in Canada to begin formalizing access for eligible patients. Rylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients one year or older who have developed hypersensitivity to E. coli-derived asparaginase. ALL and LBL are two forms of cancer that most often impact children and young adults. “We would like to thank the pCPA and its membership who recognized the need for a sustainable treatment option and worked in an expedited and collaborative manner throughout the negotiations,” says Paul Petrelli, General Manager of Jazz Pharmaceuticals Canada Inc. “Rylaze helps address the critical unmet need for a high-quality and consistently manufactured non-E. coli asparaginase treatment option, should a patient experience a hypersensitivity reaction to pegaspargase.”